SCHEMBL562443

SCHEMBL562443

COc1ccc(C=CC([O])=O)cc1OC

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.75
ALDH1A1 P00352 2/20 0.75
SMN1; SMN2 Q16637 2/20 0.75
HPGD P15428 1/20 0.75
ALOX15 P16050 1/20 0.75
MAPK1 P28482 1/20 0.75
HSD17B10 Q99714 1/20 0.75
NFE2L2 Q16236 1/20 0.73
KMT2A Q03164 4/20 0.71
ABCG2 Q9UNQ0 4/20 0.71
MEN1 O00255 2/20 0.71
TNFRSF1A P19438 1/20 0.63
JUN P05412 1/20 0.62
NFKB1 P19838 1/20 0.62
PDE4A P27815 1/20 0.61
PDE4B Q07343 1/20 0.61
PDE4C Q08493 1/20 0.61
PDE4D Q08499 1/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11584522 1.00 KDM4E (0.75) KDM4EALDH1A1SMN1; SMN2HPGDALOX15
SCHEMBL2743877 0.87 NFKB1 (0.79) KDM4EALDH1A1SMN1; SMN2HPGDALOX15
SCHEMBL30493821 0.87 NFKB1 (0.79) KDM4EALDH1A1SMN1; SMN2HPGDALOX15
SCHEMBL2743876 0.87 NFKB1 (0.79) KDM4EALDH1A1SMN1; SMN2HPGDALOX15
O,O'-Dimethylcaffeic Acid SCHEMBL1659799 0.86 KDM4E (0.71) KDM4EALDH1A1SMN1; SMN2HPGDALOX15
O,O'-Dimethylcaffeic Acid SCHEMBL1659802 0.86 KDM4E (0.71) KDM4EALDH1A1SMN1; SMN2HPGDALOX15
SCHEMBL8153885 0.86 KDM4E (0.75) KDM4EALDH1A1SMN1; SMN2HPGDALOX15
O,O'-Dimethylcaffeic Acid SCHEMBL81318 0.86 KDM4E (1.00) KDM4EALDH1A1SMN1; SMN2HPGDALOX15
SCHEMBL4937158 0.86 FDPS (0.79) KDM4EALDH1A1SMN1; SMN2HPGDALOX15
SCHEMBL4937166 0.86 FDPS (0.79) KDM4EALDH1A1SMN1; SMN2HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765761-B1 NOVEL ANALOGS OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID LAILA NUTRACEUTICALS (IN) 2013-04-03 EP claimed
US-20120035176-A1 ANALOGS OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID LAILA NUTRACEUTICALS 2012-02-09 US claimed
US-20090318551-A1 USES OF ANALOGS OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID GOKARAJU GANGA RAJU 2009-12-24 US claimed
US-7625947-B2 Analogs of 3-O-acetyl-11-keto-β-boswellic acid LAILA NUTRACEUTICALS (IN) 2009-12-01 US claimed
EP-1765761-A1 NOVEL ANALOGS OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID Gokaraju, Ganga, Raju (IN) 2007-03-28 EP claimed
US-20060089409-A1 Novel analogs of 3-o-acetyl-11-keto-ß-boswellic acid LAILA NUTRACEUTICALS (IN) 2006-04-27 US claimed
WO-2005123649-A1 NOVEL ANALOGS OF 3-O-ACETYL-11-KETO-β-BOSWELLIC ACID GOKARAJU GANGA RAJU (IN) 2005-12-29 WO claimed
US-8748598-B2 Analogs of 3-O-acetyl-11-keto-beta-boswellic acid LAILA NUTRACEUTICALS (IN) 2014-06-10 US disclosed
EP-1765761-B1 NOVEL ANALOGS OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID LAILA NUTRACEUTICALS (IN) 2013-04-03 EP disclosed
US-20120035176-A1 ANALOGS OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID LAILA NUTRACEUTICALS 2012-02-09 US disclosed
US-20090318551-A1 USES OF ANALOGS OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID GOKARAJU GANGA RAJU 2009-12-24 US disclosed
US-20090318551-A1 USES OF ANALOGS OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID GOKARAJU GANGA RAJU 2009-12-24 US disclosed
US-7625947-B2 Analogs of 3-O-acetyl-11-keto-β-boswellic acid LAILA NUTRACEUTICALS (IN) 2009-12-01 US disclosed
US-7625947-B2 Analogs of 3-O-acetyl-11-keto-β-boswellic acid LAILA NUTRACEUTICALS (IN) 2009-12-01 US disclosed
EP-1765761-A1 NOVEL ANALOGS OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID Gokaraju, Ganga, Raju (IN) 2007-03-28 EP disclosed
US-20060089409-A1 Novel analogs of 3-o-acetyl-11-keto-ß-boswellic acid LAILA NUTRACEUTICALS (IN) 2006-04-27 US disclosed
US-20060089409-A1 Novel analogs of 3-o-acetyl-11-keto-ß-boswellic acid LAILA NUTRACEUTICALS (IN) 2006-04-27 US disclosed
WO-2005123649-A1 NOVEL ANALOGS OF 3-O-ACETYL-11-KETO-β-BOSWELLIC ACID GOKARAJU GANGA RAJU (IN) 2005-12-29 WO disclosed
US-4101464-A Process for preparing foamed solids using two or more azo compounds PENNWALT CORPORATION (US) 1978-07-18 US disclosed
US-3993609-A ACID SENSITIVE AZO PROMOTERS PENNWALT CORPORATION (US) 1976-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035176-A1 ANALOGS OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID NFKBIA, ALOX12, ALOX15 KDM4E 3049/4885ALDH1A1 298/4885SMN1; SMN2 4370/4885
US-20060089409-A1 Novel analogs of 3-o-acetyl-11-keto-ß-boswellic acid KAT2B, AKR1C3, ACACB KDM4E 2773/4885ALDH1A1 431/4885SMN1; SMN2 4129/4885
US-20090318551-A1 USES OF ANALOGS OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID ACACB, KAT2B, AKR1C3 KDM4E 3024/4885ALDH1A1 378/4885SMN1; SMN2 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.